etherna immunotherapies
Niel
About etherna immunotherapies
etherna’s mission is to be a technology leader in the development of nucleic acid-based medicines which enables our partners to create new drugs and improve patients’ lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $111.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2022)
- Website: etherna.be
- Phone: +32 3 369 17 40
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/etherna-immunotherapies-37909 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.